VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has entered into a strategic collaboration with global biotechnology leader, CSL (ASX:CSL), to support the development of its lead asset, VMX-C001. VMX-C001 is a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. CSL has also entered into an exclusive option agreement with VarmX shareholders to acquire all issued and outstanding shares of the company.
VarmX Announces Appointment of John Glasspool as CEO
VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed international life sciences industry veteran John Glasspool as CEO, with immediate effect.
VarmX to Attend LSX World Congress and Bio€quity Europe in Q2 2024
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio€quity Europe (12-14 May).
VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that Dr. Jeffrey Lawson, currently the Company’s Chief Scientific Officer, will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.
VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round.
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Jeffrey Lawson as its new Chief Scientific Officer (CSO).
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
VarmX, a clinical-stage biotech company focusing on development of innovative approaches for the reversal of anticoagulation, today announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.
VarmX Awarded Funding From the EIC Accelerator to Support Scale up and Manufacturing of VMX-C001
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, has been awarded up to €17.5 million from the European Innovation Council (EIC) Accelerator, subject to negotiation, to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001.
